作者
Marc A Pfeffer, Brian Claggett, Eldrin F Lewis, Christopher B Granger, Lars Køber, Aldo P Maggioni, Douglas L Mann, John JV McMurray, Jean-Lucien Rouleau, Scott D Solomon, Philippe G Steg, Otavio Berwanger, Maja Cikes, Carmine G De Pasquale, Cara East, Alberto Fernandez, Karola Jering, Ulf Landmesser, Roxana Mehran, Béla Merkely, Freny Vaghaiwalla Mody, Mark C Petrie, Ivo Petrov, Morten Schou, Michele Senni, David Sim, Peter van der Meer, Martin Lefkowitz, Yinong Zhou, Jianjian Gong, Eugene Braunwald
发表日期
2021/11/11
期刊
New England Journal of Medicine
卷号
385
期号
20
页码范围
1845-1855
出版商
Massachusetts Medical Society
简介
Background
In patients with symptomatic heart failure, sacubitril–valsartan has been found to reduce the risk of hospitalization and death from cardiovascular causes more effectively than an angiotensin-converting–enzyme inhibitor. Trials comparing the effects of these drugs in patients with acute myocardial infarction have been lacking.
Methods
We randomly assigned patients with myocardial infarction complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both to receive either sacubitril–valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily) or ramipril (5 mg twice daily) in addition to recommended therapy. The primary outcome was death from cardiovascular causes or incident heart failure (outpatient symptomatic heart failure or heart failure leading to hospitalization), whichever occurred first.
Results
A total of 5661 patients underwent randomization; 2830 were …
学术搜索中的文章
MA Pfeffer, B Claggett, EF Lewis, CB Granger, L Køber… - New England Journal of Medicine, 2021